Sign Out
2.5/0.625 mg FC tab: Posology: The usual dose is one ACERTIL PLUS 2.5 mg/0.625 mg film-coated tablet per day as a single dose, preferably to be taken in the morning and before a meal. If blood pressure is not controlled after one month of treatment, the dose can be doubled.
Special populations: Elderly (see Precautions): Treatment should be started at the normal dose of one ACERTIL PLUS 2.5 mg/0.625 mg film-coated tablet per day.
Renal impairment (see Precautions): In severe renal impairment (creatinine clearance below 30 ml/min), treatment is contraindicated.
In patients with moderate renal impairment (creatinine clearance 30-60 ml/min), the maximum dose should be one tablet of ACERTIL PLUS 2.5 mg/0.625 mg per day.
In patients with creatinine clearance greater than or equal to 60 ml/min, no dose modification is required.
Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic impairment (see Contraindications, Precautions, and Pharmacology: Pharmacokinetics under Actions): In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose modification is required.
Paediatric population: The safety and efficacy of perindopril arginine/indapamide in the paediatric population have not yet been established. No data are available.
ACERTIL PLUS 2.5 mg/0.625 mg should not be used in children and adolescents.
Method of administration: Oral use.
5/1.25 mg FC tab: One ACERTIL PLUS 5 mg/1.25 mg film-coated tablet per day as a single dose, preferably to be taken in the morning and before a meal.
When possible individual dose titration with the components is recommended. ACERTIL PLUS 5 mg/1.25 mg film-coated tablet should be used when blood pressure is not adequately controlled on ACERTIL PLUS 2.5 mg/0.625 mg film-coated tablet (where available). When clinically appropriate, direct change from monotherapy to ACERTIL PLUS 5 mg/1.25 mg film-coated tablet may be considered.
Elderly (see Precautions): Treatment should be initiated after considering blood pressure response and renal function.
Renal impairment (see Precautions): In severe renal impairment (creatinine clearance below 30 mL/min), treatment is contraindicated.
In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), it is recommended to start treatment with adequate dosage of the free combination.
In patients with creatinine clearance ≥60 mL/min, no dose modification is required.
Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic impairment (see Contraindications, Precautions, and Pharmacology: Pharmacokinetics under Actions): In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose adjustment is required.
Paediatric population: The safety and efficacy of perindopril arginine/indapamide in the paediatric population have not yet been established.
ACERTIL PLUS 5 mg/1.25 mg should not be used in children and adolescents.
Administration: Oral route.
